# Ipamorelin vs Sermorelin: Research Comparison of Two GH Secretagogues

> Ipamorelin vs sermorelin: a ghrelin-receptor peptide versus a GHRH analog. Different receptors, different histories — sermorelin was once FDA-approved, ipamorelin never was. The mechanisms and evidence, compared and cited.

A ghrelin-receptor pulse versus a GHRH-receptor signal — two different doors to the same growth-hormone axis, with two very different regulatory histories.

## The short comparison

Ipamorelin vs sermorelin is a comparison of two peptides that both raise growth hormone but do it through completely different mechanisms — and that sit on opposite sides of the regulatory line. Ipamorelin is a ghrelin-receptor (GHS-R1a) agonist: it mimics the hunger hormone ghrelin to fire a sharp, selective growth-hormone pulse, and it has never been an approved drug [1][3]. Sermorelin is a GHRH analog — it copies the body's own growth-hormone-releasing hormone — and it was historically an FDA-approved drug (later withdrawn from the U.S. market for commercial reasons, not safety) for diagnosing and treating growth-hormone deficiency.

In plain terms: same goal, different keys, different track records. Sermorelin has a real clinical history; ipamorelin has one PK study and one failed trial [2][3]. They are sometimes discussed as alternatives and sometimes as complements, because a GHRP and a GHRH analog hit different receptors. Below, the mechanisms, the evidence, and the honest limits of each.

## Different receptors, different signals

The core distinction is receptor-level. Sermorelin binds the GHRH receptor on pituitary somatotrophs, working through the cAMP pathway — the same door the body's natural GHRH uses. Ipamorelin binds GHS-R1a, the ghrelin receptor, working through calcium signaling [1]. Because the two act on separate receptors, they are not redundant: a GHRH analog raises the underlying GHRH drive, while a GHRP like ipamorelin adds a discrete pulse on top. That complementarity is exactly why ipamorelin is more often paired with a GHRH analog (CJC-1295) than set against one — see the [ipamorelin cjc-1295](/with-cjc-1295) stack page. A 2006 clinical review of sermorelin frames the GHRH-analog approach to restoring growth-hormone secretion, useful context for the class sermorelin belongs to [12].

## Selectivity and the cortisol question

Ipamorelin's signature is selectivity. As a GHRP, it belongs to a family — GHRP-6, GHRP-2 — that historically raised ACTH, cortisol, and prolactin alongside growth hormone. Ipamorelin was engineered out of that problem: even at more than 200 times its growth-hormone ED50, it did not raise ACTH or cortisol above GHRH-induced levels [1]. Sermorelin, as a GHRH analog, never had the cortisol-spillover issue to begin with — GHRH analogs act on a pathway that does not drive the stress axis. So on the specific question of off-target hormone activation, both are relatively clean, but for different structural reasons: sermorelin by virtue of its receptor, ipamorelin by virtue of deliberate selectivity engineering.

## Evidence base and regulatory status

This is where the two diverge most sharply. Sermorelin reached real clinical use and approval as a GHRH-analog product; ipamorelin never did. Ipamorelin's human evidence is limited to a pharmacokinetic study (n=8/dose, ~2-hour half-life) [2] and a single Phase 2 trial for postoperative ileus that missed its primary endpoint (25.3 vs 32.6 hours to first tolerated meal, p=0.15) [3]. In 2024, the FDA removed ipamorelin acetate from Category 2 of the interim 503A bulk-substances list and reviewed it at the October 29, 2024 PCAC meeting, restricting compounding access. Both compounds are prohibited in sport under WADA. The practical upshot: if the question is "which one has a documented human track record," sermorelin does; if the question is "which one is the more selective, purely pulsatile growth-hormone trigger," that is ipamorelin's design — but on a much thinner and partly negative human evidence base [3].

## Can they be combined

Because they act on different receptors, sermorelin (a GHRH analog) and ipamorelin (a GHRP) are mechanistically combinable in the same way CJC-1295 and ipamorelin are — a steady GHRH-side signal plus a pulsatile ghrelin-receptor pulse. The class-level evidence that GHRP + GHRH co-administration can exceed additive growth-hormone release comes from studies of related peptides [7][8][9], not from a sermorelin + ipamorelin trial specifically. No controlled human trial has tested that particular pair for any outcome. As with every combination on this site, the mechanism is real and the finished-product evidence is absent — the pairing is a research extrapolation, not a validated protocol.

---

A trading-desk reading of the ipamorelin and combination-stack record — the selective GH pulse logged first as the one clean number, the CJC-1295 pairing read as class-level pharmacology rather than a tested product, and the failed human trial and missing long-term safety left openly unhedged; no clinic behind the console and nothing here dosed, stacked, prescribed, or sold.